Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Acquires 6,510,416 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 6,510,416 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $11.52 per share, with a total value of $74,999,992.32. Following the transaction, the director owned 15,203,995 shares in the company, valued at $175,150,022.40. This represents a 74.89% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Artiva Biotherapeutics Trading Down 1.2%

Artiva Biotherapeutics stock opened at $10.50 on Thursday. The stock has a market cap of $259.56 million, a PE ratio of -2.97 and a beta of 2.86. The stock has a 50-day moving average price of $8.00 and a 200 day moving average price of $5.52. Artiva Biotherapeutics, Inc. has a 52 week low of $1.47 and a 52 week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.8 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors have recently made changes to their positions in the business. Prelude Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $41,000. Bank of America Corp DE increased its position in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares during the period. Bridgeway Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at $53,000. Qube Research & Technologies Ltd purchased a new stake in shares of Artiva Biotherapeutics during the second quarter valued at $58,000. Finally, Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics during the second quarter valued at $67,000.

Wall Street Analysts Forecast Growth

Several analysts have commented on ARTV shares. Cantor Fitzgerald lifted their price target on Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a report on Monday. Wedbush raised their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday. HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Needham & Company LLC boosted their price target on Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Key Stories Impacting Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Ra Capital Management disclosed a purchase of 6.51 million shares at $11.52 each, a roughly $75 million insider buy that materially increased its stake in Artiva Biotherapeutics. SEC Form 4 filing
• Positive Sentiment: Needham & Company raised its price target on Artiva Biotherapeutics to $41 from $18 and kept a buy rating, implying substantial upside from current levels. Benzinga report
• Positive Sentiment: HC Wainwright reiterated a buy rating and $35 price target while raising several earnings estimates for 2026 and beyond, suggesting improving expectations for the company’s long-term earnings path.
• Positive Sentiment: Additional analyst updates from Cantor Fitzgerald and Wedbush were also described as positive, reinforcing the broader bullish sentiment around ARTV.
• Neutral Sentiment: Some HC Wainwright estimates were mixed, with certain long-term EPS forecasts lowered even as nearer-term projections improved, so the analyst picture is not uniformly optimistic.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.